metformin thiazolidine-2,4-dione-3-ide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: metformin thiazolidine-2,4-dione-3-ide
• 英文别名: thiazolidine-2,4-dione metforminate；3-(Diaminomethylidene)-1,1-dimethylguanidine;1,3-thiazolidine-2,4-dione；3-(diaminomethylidene)-1,1-dimethylguanidine;1,3-thiazolidine-2,4-dione
• 化学式: C₃H₃NO₂S*C₄H₁₁N₅
• 分子量: 246.293
• InChiKey: AWMSKPQOLJGPQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.27
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  163
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,4-噻唑烷二酮 、 二甲双胍 以 乙醇 、 水 为溶剂， 以75%的产率得到metformin thiazolidine-2,4-dione-3-ide
  参考文献：
  名称：

  [EN] METFORMIN SALTS TO TREAT TYPE2 DIABETES
  [FR] SELS DE METFORMINE POUR TRAITER LE DIABÈTE DE TYPE 2

  摘要：

  公开号：

  WO2015042495A3

文献信息

• METFORMIN SALTS TO TREAT TYPE2 DIABETES
  申请人：JIVA PHARMA, INC.

  公开号：US20160229796A1

  公开（公告）日：2016-08-11

  Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus Type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.

  本文介绍了2,4-噻唑烷二酮的甲双胍盐，用于治疗2型糖尿病、妊娠期糖尿病、多囊卵巢综合症、非酒精性脂肪肝病、冠状动脉疾病、胰腺癌、早发性青春期和其他表现胰岛素抵抗的疾病。
• Method of treating vascular insulin resistance in a normoglycemic subject based on biomarkers
  申请人：IKFE Institut fur Klinische Forschung und Entwicklung GMBH

  公开号：US10663462B2

  公开（公告）日：2020-05-26

  The invention provides compositions and methods for determining insulin resistance and/or pancreatic β-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic β-cell dysfunction in the subject.

  本发明提供了用于确定受试者胰岛素抵抗和/或胰岛β细胞功能障碍的组合物和方法。本发明还提供了根据受试者的胰岛素抵抗和/或胰岛β细胞功能障碍治疗受试者的组合物和方法。
• Biomarkers for insulin resistance and beta-cell dysfunction
  申请人：PFUETZNER Andreas

  公开号：US20100130402A1

  公开（公告）日：2010-05-27

  The invention provides compositions and methods for determining insulin resistance and/or pancreatic β-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic β-cell dysfunction in the subject.
• Biomarkers for cardiodiabetes
  申请人：PFUETZNER Andreas

  公开号：US20100130404A1

  公开（公告）日：2010-05-27

  The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.
• Biomarkers for Adipose Tissue Activity
  申请人：Pfuetzner Andreas

  公开号：US20100209350A1

  公开（公告）日：2010-08-19

  The invention provides compositions and methods for determining a subject's adipose tissue activity. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, adiponectin, resistin, PAI-1, optionally leptin and optionally visfatin. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in identifying adipose tissue activity, which is associated with various disease states including chronic or systemic inflammation, atherosclerosis and other cardiovascular risks and complications. The invention also provides methods of treating a subject and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.